Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 4 cycles Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers

NCT02123849
View directory record Official record
Conditions
Lung Carcinoma, Tobacco Use Disorder
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
Tucson, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 17, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional Results available

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

NCT02378038
View directory record Official record
Conditions
Richter's Transformation
Interventions
PNT2258
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 17, 2026, 5:43 AM EDT
Active, not recruiting Phase 2 Interventional

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

NCT04567420
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib, Fulvestrant, Adjuvant Therapy
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
19
States / cities
Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 17, 2026, 5:43 AM EDT
Not listed Phase 3 Interventional

Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma

NCT00816959
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
R-mabHDI and ABVD, ABVD
Drug
Lead sponsor
American Scitech International
Other
Eligibility
16 Years to 65 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
East Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 17, 2026, 5:43 AM EDT
Not listed Phase 1Phase 2 Interventional

Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia

NCT00319878
View directory record Official record
Conditions
Anemia, Aplastic
Interventions
Sirolimus, Cyclosporine
Drug
Lead sponsor
Office of Rare Diseases (ORD)
NIH
Eligibility
21 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2008 · Synced Sep 17, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Analgesic Effect of IV Acetaminophen in Tonsillectomies

NCT01691690
View directory record Official record
Conditions
Adenotonsillitis, Tonsillitis
Interventions
Acetaminophen (paracetamol), Normal Saline Flush, Midazolam, Sevoflurane, Nitrous Oxide/Oxygen, Propofol, Morphine, Ondansetron, Dexamethasone
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years to 9 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 17, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT01243190
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Ofatumumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 17, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional

A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)

NCT01991210
View directory record Official record
Conditions
Ovarian Cancer
Interventions
DNIB0600A, PLD
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 17, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

NCT03173560
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
lenvatinib, everolimus
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Duarte, California • Whittier, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 17, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01851733
View directory record Official record
Conditions
Glioblastoma
Interventions
MRI-guided Laser Heat Ablation (MLA), Doxorubicin, Blood draw - dendritic cells, Dynamic Susceptibility Contrast Magnetic Resonance Imaging
Device · Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 17, 2026, 5:43 AM EDT
Completed Phase 3 Interventional

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

NCT00336791
View directory record Official record
Conditions
Breast Cancer
Interventions
5-Fluorouracil, Cyclophosphamide, Doxorubicin, Paclitaxel, Epirubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 17, 2026, 5:43 AM EDT
Terminated Phase 1 Interventional Results available

A Study of TAK-951 in Participants With Cyclic Vomiting Syndrome (CVS)

NCT06768658
View directory record Official record
Conditions
Nausea and Vomitting
Interventions
TAK-951, TAK-951 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 17, 2026, 5:43 AM EDT
Completed Phase 1 Interventional Results available

Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.

NCT01041508
View directory record Official record
Conditions
Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia, Neoplasm Recurrent
Interventions
Clofarabine, Total Body Irradiation, Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil
Drug · Radiation · Other
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Columbus, Ohio • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 17, 2026, 5:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

NCT01892189
View directory record Official record
Conditions
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions
Ketamine, TAK-063, TAK-063 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 17, 2026, 5:43 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma

NCT00516191
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Liposomal Doxorubicin/Melphalan/Bortezomib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Sep 17, 2026, 5:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Comparison of Depression Interventions After Acute Coronary Syndrome

NCT01032018
View directory record Official record
Conditions
Acute Coronary Syndrome, Depression
Interventions
Problem Solving Therapy, Sertraline, citalopram, or bupropion, Standard care
Behavioral · Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
35 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 17, 2026, 5:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

NCT06388733
View directory record Official record
Conditions
Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
Interventions
Niraparib, Temozolomide
Drug
Lead sponsor
Ivy Brain Tumor Center
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 17, 2026, 5:43 AM EDT
Not listed Phase 4 Interventional

Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

NCT03767452
View directory record Official record
Conditions
Peyronie's Disease
Interventions
Xiaflex® 0.58 mg
Drug
Lead sponsor
Manhattan Medical Research Practice, PLLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 17, 2026, 5:43 AM EDT
Recruiting Phase 1 Interventional

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

NCT03219450
View directory record Official record
Conditions
Lymphocytic Leukemia
Interventions
NeoVax, Cyclophosphamide, Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 17, 2026, 5:43 AM EDT
Terminated Phase 1 Interventional

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

NCT01279291
View directory record Official record
Conditions
Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasm
Interventions
KHK2866, Gemcitabine and Carboplatin, paclitaxel, pegylated liposomal doxorubicin
Biological · Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 17, 2026, 5:43 AM EDT
Terminated Phase 3 Interventional

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

NCT04316013
View directory record Official record
Conditions
Colonic Cancer, Rectal Cancer, Non Small Cell Lung Cancer
Interventions
Sevoflurane, Propofol, Lidocaine IV
Drug
Lead sponsor
Peter MacCallum Cancer Centre, Australia
Other
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Cleveland, Ohio • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 17, 2026, 5:43 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease

NCT01731236
View directory record Official record
Conditions
Dietary Modification
Interventions
Carnitine, Choline, Antibiotics, Choline and Aspirin, Carnitine and Aspirin
Dietary Supplement · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 17, 2026, 5:43 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3022855 In Participants With Breast or Prostate Cancer

NCT02265536
View directory record Official record
Conditions
Neoplasms, Neoplasm Metastasis
Interventions
LY3022855
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 17, 2026, 5:43 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Donepezil Memory Preservation Post ECT

NCT02331771
View directory record Official record
Conditions
Memory Impairment
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Porter Adventist Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 17, 2026, 5:43 AM EDT